Avid Bioservices Inc (CDMO)

[freethemice]

As it states in the abstract for the phase II trial the 30 months vs 13 was only for the SUBGROUP with stage IIIB
loco-regional disease. There were 35 patients in the SUBGROUP receiving BLP25 + BSC and 30 patients
in the SUBGROUP receiving only BSC. The whole trial had 88 patients receiving BLP25 + BSC and 83 patients
in the BSC only arm, total is 171. This is a very different patient population than in any of the bavi trials.
http://link.springer.com/article/10.1007%2Fs00432-011-1003-3

Again note that the phase III trial excluded patients with stage IV disease.